Almost a third of patients with aggressive lymphoma remained cancer free 10 years after treatment with CAR T-cell therapy. The long-term data indicate that CD19-directed CAR T-cell therapy may cure ...

Chimeric antigen receptor (CAR) T-cell therapy has significantly improved the outcome of patients with relapsed/refractory (R/R) B-cell precursor acute lymphoblastic leukemia (B-ALL). Several CAR ...

Creative Biolabs introduces metabolic-enhanced CAR-T development solutions to overcome T-cell exhaustion challenges ...

Although CD19 and CD20 antigens are expressed on most B cells, B cell maturation antigen (BCMA; TNFRSF17) is predominantly expressed on plasma cells (PCs) and plasmacytoid dendritic cells (pDCs), ...

Adam Feuerstein, a senior writer and biotech columnist, is the author of Adam’s Biotech Scorecard, a subscriber-only newsletter about the crossroads of drug development, business, Wall Street, and ...

A study published in the Journal of Clinical Oncology confirms that one of the first Food and Drug Administration-approved CAR-T cell therapies offers long-term survival and potential cures for adult ...

HLA sensitization poses a major challenge to kidney transplantation for patients with end-stage kidney disease, especially for highly sensitized candidates. Attempts at antibody elimination ...

CAR-T therapy has transformed treatment for some blood cancers, with seven FDA-approved products and strong clinical responses in hematologic malignancies. However, its limitations remain evident. In ...

UCLA scientists have developed a next-generation CAR-T cell therapy that can overcome the immunosuppressive tumor microenvironment, a protective shield that tumors use to weaken immune cells, block ...

In patients with autoimmune hemolytic anemia (AIHA), the risk of relapse is high owing to persistent autoreactive B-cell activity. Multirefractory AIHA is a more advanced stage of disease that is ...

Please provide your email address to receive an email when new articles are posted on . CAR T-cell therapy for cancer may be associated with new-onset autoimmune disease. Autoimmune events in after ...

CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, ...